CCL20 and squamous cell carcinoma: A number of chemokine/chemokine receptor antagonists are being developed for tumour immunotherapy and it remains to be seen whether blocking of CCR6/CCL20 would impact on immunosuppression in squamous cell cancers [29], [30].